Top

Published in:

Open Access 01-12-2023 | Ovarian Cancer | Research

LncRNA GAS5-hnRNPK axis inhibited ovarian cancer progression via inhibition of AKT signaling in ovarian cancer cells

Authors: Te Zhang, Yahui Leng, Mengjing Duan, Zihang Li, Yongqing Ma, Chengyang Huang, Qin Shi, Yi Wang, Chengcheng Wang, Dandan Liu, Xuan Zhao, Shuang Cheng, Ao Liu, Yang Zhou, Jiaqi Liu, Zhongqiu Pan, Huimei Zhang, Li Shen, Hongyan Zhao

Published in: Discover Oncology | Issue 1/2023

Abstract

Background

The incidence of ovarian cancer ranks third among gynecologic malignancies, but the mortality rate ranks first.

Methods

The expression of GAS5 is low in ovarian cancer and is associated with the low survival of ovarian cancer patients according to public ovarian cancer databases. GAS5 overexpression inhibited ovarian malignancy by affecting the proliferation and migratory abilities in OVCAR3 and A2780 cells. GAS5 overexpression increased the rate of cell apoptosis, and the cells were blocked in the G1 phase as assessed by flow cytometry.

Results

We found that hnRNPK was a potential target gene, which was regulated negatively by GAS5 based on RNA-pulldown and mass spectrometry analysis. Mechanistically, GAS5 affected the inhibition of the PI3K/AKT/mTOR pathways and bound the protein of hnRNPK, which influenced hnRNPK stability. Furthermore, rescue assays demonstrated hnRNPK was significantly involved in the progression of ovarian cancer.

Conclusions

Our study showed one of the mechanisms that GAS5 inhibited ovarian cancer metastasis by down-regulating hnRNPK expression, and GAS5 can be used to predict the prognosis of ovarian cancer patients.

Graphical Abstract

Available only for authorised users

Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(05):584–90.CrossRefPubMedPubMedCentral

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics. CA Cancer J Clin. 2022;72(1):7–33.CrossRefPubMed

Miller KD, Ortiz AP, Pinheiro PS, Bandi P, Minihan A, Fuchs HE, Martinez Tyson D, Tortolero-Luna G, Fedewa SA, Jemal AM. Cancer statistics for the US Hispanic/Latino population. CA Cancer J Clin. 2021;71(6):466–87.CrossRefPubMed

Grammatikakis I, Lal A. Significance of lncRNA abundance to function. Mamm Genome. 2022;33(2):271–80.CrossRefPubMed

Alessio E, Bonadio RS, Buson L, Chemello F, Cagnin S. A single cell but many different transcripts: a journey into the world of long non-coding RNAs. Int J Mol Sci. 2020;21(1):302.CrossRefPubMedPubMedCentral

Li C, Ni Y-Q, Xu H, Xiang Q-Y, Zhao Y, Zhan J-K, He J-Y, Li S, Liu Y-S. Roles and mechanisms of exosomal non-coding RNAs in human health and diseases. Signal Transduct Target Ther. 2021;6(1):383.CrossRefPubMedPubMedCentral

Ganguly N, Chakrabarti S. Role of long non-coding RNAs and related epigenetic mechanisms in liver fibrosis. Int J Mol Med. 2021;47(3):1–1.CrossRef

Wu M, Yang L-Z, Chen L-L. Long noncoding RNA and protein abundance in lncRNPs. RNA. 2021;27(12):1427–40.CrossRefPubMedPubMedCentral

Agostini M, Mancini M, Candi E. Long non-coding RNAs affecting cell metabolism in cancer. Biol Direct. 2022;17(1):1–12.CrossRef

10.

Yan H, Bu P. Non-coding RNA in cancer. Essays Biochem. 2021;65(4):625–39.CrossRefPubMedPubMedCentral

11.

Goustin AS, Thepsuwan P, Kosir MA, Lipovich L. The growth-arrest-specific (GAS)-5 long non-coding RNA: a fascinating lncRNA widely expressed in cancers. Non-Coding RNA. 2019;5(3):46.CrossRefPubMedPubMedCentral

12.

Schneider C, King RM, Philipson L. Genes specifically expressed at growth arrest of mammalian cells. Cell. 1988;54(6):787–93.CrossRefPubMed

13.

Chi Y, Wang D, Wang J, Yu W, Yang J. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019;8(9):1015.CrossRefPubMedPubMedCentral

14.

Lin G, Wu T, Gao X, He Z, Nong W. Research progress of long non-coding RNA GAS5 in Malignant Tumors. Front Oncol. 2022;12:846497.CrossRefPubMedPubMedCentral

15.

Liu Y, Yin L, Chen C, Zhang X, Wang S. Long non-coding RNA GAS5 inhibits migration and invasion in gastric cancer via interacting with p53 protein. Dig Liver Dis. 2020;52(3):331–8.CrossRefPubMed

16.

Li Y, Wang H, Wan J, Ma Q, Qi Y, Gu Z. The hnRNPK/A1/R/U complex regulates gene transcription and translation and is a favorable prognostic biomarker for human colorectal adenocarcinoma. Front Oncol. 2022. https://doi.org/10.3389/fonc.2022.845931.CrossRefPubMedPubMedCentral

17.

Puvvula PK, Buczkowski S, Moon AM. hnRNPK-derived cell-penetrating peptide inhibits cancer cell survival. Mol Ther Oncolytics. 2021;23:342–54.CrossRefPubMedPubMedCentral

18.

Wang Z, Chen J, Sun F, Zhao X, Dong Y, Yu S, Li J, Liang H. LncRNA CRLM1 inhibits apoptosis and promotes metastasis through transcriptional regulation cooperated with hnRNPK in colorectal cancer. Cell Biosci. 2022;12(1):1–21.CrossRef

19.

Herman AB, Tsitsipatis D, Gorospe M. Integrated lncRNA function upon genomic and epigenomic regulation. Mol Cell. 2022;82(12):2252–66.CrossRefPubMedPubMedCentral

20.

Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S, Caesar-Johnson SJ, Demchok JA. lncRNA epigenetic landscape analysis identifies EPIC1 as an oncogenic lncRNA that interacts with MYC and promotes cell-cycle progression in cancer. Cancer cell. 2018;33(4):706-720. e709.CrossRefPubMedPubMedCentral

21.

Hu WL, Jin L, Xu A, Wang YF, Thorne RF, Zhang XD, Wu M. GUARDIN is a p53-responsive long non-coding RNA that is essential for genomic stability. Nat Cell Biol. 2018;20(4):492–502.CrossRefPubMed

22.

Ni W, Yao S, Zhou Y, Liu Y, Huang P, Zhou A, Liu J, Che L, Li J. Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m6A reader YTHDF3. Mol Cancer. 2019;18(1):1–20.CrossRef

23.

Yu X, Ye Z, Hou L, Zhang X, Liu Z, Wu R, Huang F, Wang G, Geng X, Zhao H. Hepatitis B virus x gene-downregulated growth-arrest specific 5 inhibits the cell viability and invasion of hepatocellular carcinoma cell lines by activating Y-box-binding protein 1/p21 signaling. J Cell Commun Signal. 2021. https://doi.org/10.1007/s12079-021-00645-z.CrossRefPubMedPubMedCentral

24.

Yao ZT, Yang YM, Sun MM, He Y, Liao L, Chen KS, Li B. New insights into the interplay between long non-coding RNAs and RNA-binding proteins in cancer. Cancer Commun. 2022;42(2):117–40.CrossRef

25.

Sun X, Haider Ali MSS, Moran M. The role of interactions of long non-coding RNAs and heterogeneous nuclear ribonucleoproteins in regulating cellular functions. Biochem J. 2017;474(17):2925–35.CrossRefPubMed

26.

Li H, Liu JW, Shen SX, Dai D, Cheng ST, Dong XL, Sun LP, Guo XL. Pan-cancer analysis of alternative splicing regulator heterogeneous nuclear ribonucleoproteins (hnRNPs) family and their prognostic potential. J Cell Mol Med. 2020;24(19):11111–9.CrossRefPubMedCentral

27.

Sudhakaran M, Doseff AI. Role of heterogeneous nuclear ribonucleoproteins in the cancer-immune landscape. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms24065086.CrossRefPubMedPubMedCentral

28.

Shishkin SS, Kovalev LI, Pashintseva NV, Kovaleva MA, Lisitskaya K. Heterogeneous nuclear ribonucleoproteins involved in the functioning of telomeres in malignant cells. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20030745.CrossRefPubMedPubMedCentral

29.

Moran-Jones K, Grindlay J, Jones M, Smith R, Norman JC. hnRNP A2 regulates alternative mRNA splicing of TP53INP2 to control invasive cell migration. Cancer Res. 2009;69(24):9219–27.CrossRefPubMedPubMedCentral

30.

Patry C, Bouchard L, Labrecque P, Gendron D, Lemieux B, Toutant J, Lapointe E, Wellinger R, Chabot B. Small interfering RNA-mediated reduction in heterogeneous nuclear ribonucleoparticule A1/A2 proteins induces apoptosis in human cancer cells but not in normal mortal cell lines. Cancer Res. 2003;63(22):7679–88.PubMed

31.

Yang Y, Wei Q, Tang Y, Yuanyuan W, Luo Q, Zhao H, He M, Wang H, Zeng Q, Lu W, et al. Loss of hnRNPA2B1 inhibits malignant capability and promotes apoptosis via down-regulating Lin28B expression in ovarian cancer. Cancer Lett. 2020;475:43–52.CrossRefPubMed

32.

Qin H, Ni H, Liu Y, Yuan Y, Xi T, Li X, Zheng L. RNA-binding proteins in tumor progression. J Hematol Oncol. 2020;13(1):1–23.CrossRef

33.

Hentze MW, Castello A, Schwarzl T, Preiss T. A brave new world of RNA-binding proteins. Nat Rev Mol Cell Biol. 2018;19(5):327–41.CrossRefPubMed

34.

Wang Z, Qiu H, He J, Liu L, Xue W, Fox A, Tickner J, Xu J. The emerging roles of hnRNPK. J Cell Physiol. 2020;235(3):1995–2008.CrossRefPubMed

35.

Xu Y, Wu W, Han Q, Wang Y, Li C, Zhang P, Xu H. Post-translational modification control of RNA-binding protein hnRNPK function. Open Biol. 2019;9(3):180239.CrossRefPubMedPubMedCentral

36.

Xu Y, Wu W, Han Q, Wang Y, Li C, Zhang P, Xu H. New insights into the interplay between non-coding RNAs and RNA-binding protein HnRNPK in regulating cellular functions. Cells. 2019;8(1):62.CrossRefPubMedPubMedCentral

37.

Tewari D, Patni P, Bishayee A, Sah AN, Bishayee A. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy. Semin Cancer Biol. 2022. https://doi.org/10.1016/j.semcancer.2019.12.008.CrossRefPubMedPubMedCentral

38.

Fath MK, Ebrahimi M, Nourbakhsh E, Hazara AZ, Mirzaei A, Shafieyari S, Salehi A, Hoseinzadeh M, Payandeh Z, Barati G. PI3K/Akt/mTOR signaling pathway in cancer stem cells. Pathol Res Pract. 2022. https://doi.org/10.1016/j.prp.2022.154010.CrossRef

39.

Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin Cancer Biol. 2019. https://doi.org/10.1016/j.semcancer.2019.05.012.CrossRefPubMed

Title: LncRNA GAS5-hnRNPK axis inhibited ovarian cancer progression via inhibition of AKT signaling in ovarian cancer cells
Authors: Te Zhang
Yahui Leng
Mengjing Duan
Zihang Li
Yongqing Ma
Chengyang Huang
Qin Shi
Yi Wang
Chengcheng Wang
Dandan Liu
Xuan Zhao
Shuang Cheng
Ao Liu
Yang Zhou
Jiaqi Liu
Zhongqiu Pan
Huimei Zhang
Li Shen
Hongyan Zhao
Publication date: 01-12-2023
Publisher: Springer US
Keywords: Ovarian Cancer
Ovarian Cancer
Published in: Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-023-00764-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Graphical Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

A demonstration based on multi-omics transcriptome sequencing data revealed disulfidptosis heterogeneity within the tumor microenvironment of esophageal squamous cell carcinoma

Ovarian clear cell carcinoma with or without endometriosis origin in a single institution cohort

Integrating TCGA and single-cell sequencing data for colorectal cancer: a 10-gene prognostic risk assessment model

Prognostic value of the combined preoperative plasma fibrinogen and systemic inflammatory indexes in ESCC patients

Using machine learning-based radiomics to differentiate between glioma and solitary brain metastasis from lung cancer and its subtypes

MTHFR act as a potential cancer biomarker in immune checkpoints blockades, heterogeneity, tumor microenvironment and immune infiltration

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials